Explore 3 Stock Ideas & Industry Insights Download Free Report

News

West Pharmaceutical CEO Receives Stock Options and RSUs

Michel Lagarde, President and CEO of West Pharmaceutical Services Inc, filed a Form 4 on September 10, 2026, disclosing the acquisition of stock options and restricted stock units granted on September 8, 2026.

Nitish Kishor | 10 September 2026

WisdomTree President and COO Sells 30,000 Shares

A Form 4 filed on September 10, 2026 disclosed that Jarrett R. Lilien, President and Chief Operating Officer of WisdomTree, Inc. (NYSE:WT), sold 30,000 shares of common stock on September 9, 2026 under a pre-established Rule 10b5-1 trading plan.

Anjali Anand | 10 September 2026

Oragenics (NYSE American:OGEN) Stock: A Listing Notice Overshadows Clinical Progress

Once known for early-stage antibiotics and probiotics work, Oragenics Inc (NYSE American:OGEN) has reinvented itself as a neuroscience-focused developer built around intranasal drug delivery for brain injury. The company, listed on NYSE American under the ticker OGEN, is a sub-dollar micro-cap advancing a mid-stage …

Nitish Kishor | 10 September 2026

OKYO Pharma (NASDAQ:OKYO) Slides: What Investors Need to Know

● A single-session dip of around 5% barely registers as news for a development-stage biotech, and in the case of OKYO Pharma the recent slide arrives against an otherwise constructive backdrop.

Nitish Kishor | 10 September 2026

Oncolytics Biotech (NASDAQ:ONCY) Shares Slip: What's Pressuring ONCY and What Comes Next?

● Oncolytics Biotech is a Calgary-based, Nasdaq-listed clinical-stage biotechnology company developing pelareorep, an intravenously administered formulation of a reovirus designed to stimulate an anti-tumor immune response.

Nitish Kishor | 10 September 2026

Oncotelic Therapeutics, Inc. (OTC:OTLC) Stock Gains Ground: Is It Quietly Building Momentum?

● The modest one-day rise does not map to a single confirmed same-session catalyst; at fractions of a cent, OTLC moves are heavily influenced by thin liquidity.

Nitish Kishor | 10 September 2026

OncoVista (OTC:OVIT) Deregistered From the SEC a Decade Ago and Never Looked Back

OncoVista Innovative Therapies, Inc. (OTC:OVIT) is one of those names that lingers on quote screens long after the working company behind it has gone quiet. Once a San Antonio-based clinical-stage pharmaceutical developer with ambitions in oncology, OncoVista today trades as a sub-penny shell, priced …

Nitish Kishor | 10 September 2026

Prestige Consumer Healthcare Inc (NYSE:PBH) Shares Slip: What's Pressuring It and What Comes Next?

● Despite If anything, attention around Prestige has centered on its acquisition-driven growth strategy and the addedLeveragefrom the senior notes offering.

Nitish Kishor | 10 September 2026

PDS Biotechnology (NASDAQ:PDSB) Stock: Is the Pullback Creating a New Setup

PDS Biotechnology Corporation (NASDAQ:PDSB) has spent 2026 trying to prove that its lead cancer immunotherapy can reach the market faster, even as its share price has slid toward penny-stock territory. The supplied headline frames a "drift lower" and asks whether the pullback is creating …

Nitish Kishor | 10 September 2026

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Drop: Why PHAT Is Under Pressure

● Commercial-stage biopharma stocks can be punished even when sales are climbing, and Phathom Pharmaceuticals has felt that tension in 2026.

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…